IBRORS-MCL study: a Spanish retrospective and observational study of relapsed/refractory mantle-cell lymphoma treated with ibrutinib in routine clinical practice
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Sancho, Juan Manuel
- dc.contributor.author Salar Silvestre, Antonio
- dc.contributor.author Rubio-Azpeitia, Eva
- dc.date.accessioned 2023-01-31T07:14:37Z
- dc.date.available 2023-01-31T07:14:37Z
- dc.date.issued 2022
- dc.description.abstract This retrospective study evaluated 66 patients diagnosed with relapsed and/or refractory mantle cell lymphoma (R/R MCL) treated with ibrutinib in Spain in routine clinical practice. At diagnosis, patients had a median age of 64.5 years, 63.6% presented with intermediate/high sMIPI (simplified prognostic index for advanced-stage mantle cell lymphoma), 24.5% had the blastoid variant, and 55.6% had a Ki67 > 30%. Patients had received a median of 2 prior lines of therapy (range 1-2; min-max 1-7). Overall response rate was 63.5%, with 38.1% of patients achieving complete response (CR). With a median duration of ibrutinib exposure of 10.7 months (range 5.2-19.6; min-max 0.3-36), the median progression-free survival (PFS) and overall survival (OS) were 20 months [95% confidence interval (CI) 8.8-31.1] and 32 months (95% CI 22.6-41.3), respectively, and were not reached in patients achieving CR. No grade ≥ 3 cardiovascular toxicity or bleeding was reported. This study supports that treatment with ibrutinib leads to high response rates and favorable survival outcomes in patients with R/R MCL.
- dc.format.mimetype application/pdf
- dc.identifier.citation Sancho JM, Marín-Niebla A, Fernández S, Capote FJ, Cañigral C, Grande C et al. IBRORS-MCL study: a Spanish retrospective and observational study of relapsed/refractory mantle-cell lymphoma treated with ibrutinib in routine clinical practice. Int J Hematol. 2022 Sep;116(3):381-92. DOI: 10.1007/s12185-022-03367-z
- dc.identifier.doi http://dx.doi.org/10.1007/s12185-022-03367-z
- dc.identifier.issn 0925-5710
- dc.identifier.uri http://hdl.handle.net/10230/55489
- dc.language.iso eng
- dc.publisher Springer
- dc.relation.ispartof Int J Hematol. 2022 Sep;116(3):381-92
- dc.rights © The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
- dc.rights.accessRights info:eu-repo/semantics/openAccess
- dc.rights.uri http://creativecommons.org/licenses/by/4.0/
- dc.subject.keyword Clinical practice
- dc.subject.keyword Ibrutinib
- dc.subject.keyword Mantle-cell lymphoma
- dc.subject.keyword Real-world evidence
- dc.subject.keyword Relapsed/refractory
- dc.title IBRORS-MCL study: a Spanish retrospective and observational study of relapsed/refractory mantle-cell lymphoma treated with ibrutinib in routine clinical practice
- dc.type info:eu-repo/semantics/article
- dc.type.version info:eu-repo/semantics/publishedVersion